PGEN
What one share of Precigen holds
Pharmaceutical Preparations
We are a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve the lives of patients. We are leveraging our proprietary technology platforms to develop product candidates designed to target urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.23 |
|---|---|
| Profit | −$0.42 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.31 |
| Cash and investments | $0.05 |
| Debt | $0.26 |
| Book value | $0.12 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2011 | $1.53 | −$18.92 | $2.48 | −$18.08 | — | −$42.22 |
| 2012 | $2.49 | −$18.77 | $1.35 | −$12.47 | — | −$56.80 |
| 2013 | $0.58 | −$1.40 | $0.04 | −$1.35 | — | — |
| 2014 | $0.73 | −$0.83 | $0.06 | −$0.26 | — | $3.83 |
| 2015 | $1.56 | −$0.76 | $0.11 | $0.21 | — | $5.95 |
| 2016 | $1.62 | −$1.58 | $0.27 | −$0.68 | — | $4.72 |
| 2017 | $1.92 | −$0.98 | $0.39 | −$1.25 | — | $4.37 |
| 2018 | $1.17 | −$3.93 | $0.32 | −$1.28 | — | $2.27 |
| 2019 | $0.59 | −$2.09 | $0.25 | −$1.13 | — | $0.44 |
| 2020 | $0.19 | −$1.02 | $0.05 | −$0.51 | — | $0.36 |
| 2021 | $0.07 | −$0.47 | $0.04 | −$0.32 | — | $0.52 |
| 2022 | $0.13 | $0.14 | $0.02 | −$0.35 | — | $0.61 |
| 2023 | $0.03 | −$0.39 | $0.01 | −$0.28 | — | $0.48 |
| 2024 | $0.01 | −$0.47 | $0.03 | −$0.29 | — | $0.13 |
| 2025 | $0.03 | −$1.37 | $0.01 | −$0.29 | — | $0.06 |